SCHEMBL1658824

SCHEMBL1658824

CC(=O)Nc1ccc2c(c1C)CCC2=O

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.43
ALDH1A1 P00352 6/20 0.40
HPGD P15428 3/20 0.40
KDM4E B2RXH2 6/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
HSD17B10 Q99714 2/20 0.37
CXCR2 P25025 1/20 0.37
MAOA P21397 1/20 0.36
GAA P10253 3/20 0.36
KDR P35968 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30957414 0.83 BAZ2B (0.42) BAZ2BALDH1A1HPGDKDM4ENPC1
SCHEMBL15300166 0.83 BAZ2B (0.42) BAZ2BALDH1A1HPGDKDM4ENPC1
SCHEMBL5582059 0.83 BAZ2B (0.46) BAZ2BALDH1A1HPGDKDM4ENPC1
SCHEMBL4814588 0.79 NPC1 (0.56) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL10620933 0.74 ALDH1A1 (0.58) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL12597861 0.74 CRBN (0.38) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL5726927 0.74 ALDH1A1 (0.34) BAZ2BALDH1A1HPGDKDM4ENPC1
SCHEMBL11102779 0.73 ALDH1A1 (0.36) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL9288475 0.72 ALDH1A1 (0.47) BAZ2BALDH1A1HPGDKDM4ENPC1
SCHEMBL5727226 0.72 PDE3B (0.38) BAZ2BALDH1A1HPGDKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1943224-B1 ESTROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2011-07-27 EP disclosed
EP-1943224-B1 ESTROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2011-07-27 EP disclosed
US-7923568-B2 Estrogen receptor modulators MERCK SHARP & DOHME CORP. (US) 2011-04-12 US disclosed
US-7923568-B2 Estrogen receptor modulators MERCK SHARP & DOHME CORP. (US) 2011-04-12 US disclosed
US-7923568-B2 Estrogen receptor modulators MERCK SHARP & DOHME CORP. (US) 2011-04-12 US disclosed
US-20100168188-A1 Estrogen Receptor Modulators MERCK SHARP & DOHME LLC 2010-07-01 US disclosed
US-20100168188-A1 Estrogen Receptor Modulators MERCK SHARP & DOHME LLC 2010-07-01 US disclosed
US-20100168188-A1 Estrogen Receptor Modulators MERCK SHARP & DOHME LLC 2010-07-01 US disclosed
EP-1943224-A4 ESTROGEN RECEPTOR MODULATORS MERCK & CO INC (US) 2009-07-15 EP disclosed
EP-1943224-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2008-07-16 EP disclosed
WO-2007089291-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed
WO-2007089291-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed
US-20070087346-A1 Orthogonal gene switches CILIBERTO GENNARO 2007-04-19 US disclosed
US-20070087346-A1 Orthogonal gene switches CILIBERTO GENNARO 2007-04-19 US disclosed
EP-1680447-A2 ORTHOGONAL GENE SWITCHES ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2006-07-19 EP disclosed
EP-1339683-B1 ESTROGEN RECEPTOR MODULATORS MERCK & CO INC (US) 2006-06-14 EP disclosed
EP-1339683-A4 ESTROGEN RECEPTOR MODULATORS MERCK & CO INC (US) 2005-07-27 EP disclosed
WO-2005040212-A2 ORTHOGONAL GENE SWITCHES ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2005-05-06 WO disclosed
EP-1339683-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2003-09-03 EP disclosed
WO-2002041835-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168188-A1 Estrogen Receptor Modulators ESR2, GPER1, ESRRA BAZ2B 1608/4885ALDH1A1 1883/4885HPGD 809/4885
US-20070087346-A1 Orthogonal gene switches TCF12, JUN, TCF7 BAZ2B 219/4885ALDH1A1 3117/4885HPGD 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.